Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 7971632.
- Also identified by PMC identifier 2397734.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fludarabine is one of the most recent and promising therapeutic agents for chronic lymphocytic leukaemia. We describe a patient who developed tumour lysis syndrome after the first course of treatment with fludarabine and call attention to this uncommon but potentially lethal complication that has not been previously taken into account in this neoplasia. It should always be anticipated when patients are treated with new and effective drugs.
Medical subject headings
- Antineoplastic Agents
- Leukemia, Lymphocytic, Chronic, B-Cell
- Tumor Lysis Syndrome
- Vidarabine